Harrow (HROW) Share-based Compensation Growth (3y) (2013 - 2026)
Harrow (HROW) Share-based Compensation Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 10.06% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 9.14% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 0.43% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -8.13% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -1.73% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -8.04% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Harrow | 1.56 Bn | 1.47 Bn | 50.36 Mn | -11.21% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -11.21% |
| Mar 31, 2026 | 32.94% |
| Dec 31, 2025 | -13.08% |
| Sep 30, 2025 | 19.17% |
| Jun 30, 2025 | -24.00% |
| Mar 31, 2025 | 63.84% |
| Dec 31, 2024 | 31.36% |
| Sep 30, 2024 | 37.22% |
| Jun 30, 2024 | 58.24% |
| Mar 31, 2024 | 69.57% |
| Dec 31, 2023 | 81.61% |
| Sep 30, 2023 | 69.63% |
| Jun 30, 2023 | 105.02% |
| Mar 31, 2023 | 45.24% |
| Dec 31, 2022 | 52.26% |
| Sep 30, 2022 | 195.34% |
| Jun 30, 2022 | 75.77% |
| Mar 31, 2022 | 9.55% |
| Dec 31, 2021 | 269.28% |
| Sep 30, 2021 | 41.26% |